Amphastar Pharmaceuticals, Inc. (AMPH) is a Healthcare stock trading at $21.60 (as of 2026-08-21), with a market capitalization of $952.41M and a trailing P/E of 15.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Amphastar Pharmaceuticals develops, manufactures, and sells generic and proprietary injectable, inhalation, and intranasal drugs, in the US, China, and France, and it earns money from product sales through finished pharmaceutical products and its API segment.
Amphastar’s profit engine is the sale of finished pharmaceutical products (generic and proprietary drugs such as Primatene Mist, Paximi/Baximi, and other injectables), with the API segment functioning as a separate business line.
| Finished | $0.2B |
| API | $0.0B |
Business quality (Weak): Segment information is clear (Finished Pharmaceutical Products and API), but the API segment revenue appears at 0.0 in the provided data, and the set of operating KPIs provided does not include a single broad, widely standardized operational measure like demand volume or retention.
Valuation: At 12× earnings, AMPH trades 28% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $21.60 |
| Market Cap | $952.41M |
| P/E Ratio | 15.7 |
| EV / EBITDA | 5.3 |
| Price / Book | 1.24 |
| Price / Sales | 1.33 |
| FCF Yield | 26.7% |
| DCF Value (model) | $32.76 |
| DCF Upside vs Price | 51.7% |
| Revenue (TTM) | $719.89M |
| Net Margin | 13.6% |
| Revenue Growth (YoY) | -1.7% |
| EPS Growth (YoY) | -36.2% |
| FCF Growth (YoY) | -29.7% |
| Altman Z-Score | 2.35 (grey) |
| Piotroski F-Score | 6/9 (moderate) |
| Stock P/E | 15.7 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -27.6% |
| vs Industry | -8.4% |
| Top Institutional Holder | BlackRock, Inc. ($106.20M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Yongfeng Zhang |
| Employees | 2,028 |
| Country | US |
| IPO Date | 2014-06-25 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.